Best Practice & Research Clinical Haematology最新文献_第8页

Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors 临床血液学的最佳实践与研究:霍奇金淋巴瘤幸存者的乳腺癌筛查

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-11-25 DOI: 10.1016/j.beha.2023.101525

Stephanie M. Wong

{"title":"Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors","authors":"Stephanie M. Wong","doi":"10.1016/j.beha.2023.101525","DOIUrl":"https://doi.org/10.1016/j.beha.2023.101525","url":null,"abstract":"<div>Childhood and young adult survivors of Hodgkin lymphoma are at an elevated risk of developing breast cancer. Breast cancer risk is felt to originate from chest wall radiation exposure prior to the third decade of life, with incidence beginning to rise approximately eight to ten years following Hodgkin lymphoma treatment. Although incidence varies according to age at radiation exposure, dosage, and treatment fields, cohort studies have documented a cumulative incidence of breast cancer of 10–20% by 40 years of age. Women with a history of chest radiation for Hodgkin lymphoma are counselled to begin screening with bilateral breast MRI at 25 years of age, or eight years after radiation, whichever occurs later. Outside of high-risk surveillance, the optimal management approach for women with prior radiation exposure continues to evolve. When diagnosed with breast malignancy, evidence supports consideration of unilateral therapeutic and contralateral prophylactic mastectomy, although breast conserving surgery may be considered following multidisciplinary assessment. This review will address the epidemiology, characteristics, screening and management guidelines, and breast-cancer prevention efforts for Hodgkin lymphoma survivors treated with radiation therapy in adolescence and young adulthood.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 4","pages":"Article 101525"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138474992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When to use which molecular prognostic scoring system in the management of patients with MDS? 在MDS患者的管理中，何时使用哪种分子预后评分系统?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-10-17 DOI: 10.1016/j.beha.2023.101517

Tariq Kewan , Jan Philipp Bewersdorf , Carmelo Gurnari , Zhuoer Xie , Maximilian Stahl , Amer M. Zeidan

{"title":"When to use which molecular prognostic scoring system in the management of patients with MDS?","authors":"Tariq Kewan , Jan Philipp Bewersdorf , Carmelo Gurnari , Zhuoer Xie , Maximilian Stahl , Amer M. Zeidan","doi":"10.1016/j.beha.2023.101517","DOIUrl":"https://doi.org/10.1016/j.beha.2023.101517","url":null,"abstract":"<div>Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematopoietic cancers characterized by recurrent molecular alterations driving the disease pathogenesis with a variable propensity for progression to acute myeloid leukemia (AML). Clinical decision making for MDS relies on appropriate risk stratification at diagnosis, with higher-risk patients requiring more intensive therapy. The conventional clinical prognostic systems including the International Prognostic Scoring System (IPSS) and its revised version (IPSS-R) have dominated the risk stratification of MDS from 1997 until 2022. Concurrently, the use of next-generation sequencing has revolutionized the field by revealing multiple recurrent genetic mutations, which correlate with phenotype and prognosis. Significant efforts have been made to formally incorporate molecular data into prognostic tools to improve proper risk identification and personalize treatment strategies. In this review, we will critically compare the available molecular scoring systems for MDS focusing on areas of progress and potential limitations that can be improved in subsequent revisions of these tools.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 4","pages":"Article 101517"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91987017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The international cooperative Gaucher group (ICCG) Gaucher registry 国际合作戈歇组织(ICCG)戈歇注册

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-10-31 DOI: 10.1016/j.beha.2023.101522

Neal J. Weinreb

引用次数: 0

Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors 对低甲基化药物和BCL-2抑制剂的耐药性机制

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-10-20 DOI: 10.1016/j.beha.2023.101521

Sudhamsh Reddy Desai , Samarpana Chakraborty , Aditi Shastri

引用次数: 0

The best GVHD prophylaxis: Or at least progress towards finding it 最好的GVHD预防方法:或者至少朝着找到它的方向前进

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-10-20 DOI: 10.1016/j.beha.2023.101520

Daniel Weisdorf , Najla El Jurdi , Shernan G. Holtan

引用次数: 0

Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new” b细胞非霍奇金淋巴瘤的细胞基因组学:“老”与“新”的相遇

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-10-10 DOI: 10.1016/j.beha.2023.101513

Marta Grau , Cristina López , José Ignacio Martín-Subero , Sílvia Beà

{"title":"Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”","authors":"Marta Grau , Cristina López , José Ignacio Martín-Subero , Sílvia Beà","doi":"10.1016/j.beha.2023.101513","DOIUrl":"https://doi.org/10.1016/j.beha.2023.101513","url":null,"abstract":"<div>For the routine diagnosis of haematological neoplasms an integrative approach is used considering the morphology, and the immunophenotypic, and molecular features of the tumor sample, along with clinical information. The identification and characterization of recurrent chromosomal aberrations mainly detected by conventional and molecular cytogenetics in the tumor cells has a major impact on the classification of lymphoid neoplasms. Some of the B-cell non-Hodgkin lymphomas are characterized by particular chromosomal aberrations, highlighting the relevance of conventional and molecular cytogenetic studies in their diagnosis and prognosis. In the current genomics era, next generation sequencing provides relevant information as the mutational profiles of haematological malignancies, improving their classification and also the clinical management of the patients. In addition, other new technologies have emerged recently, such as the optical genome mapping, which can overcome some of the limitations of conventional and molecular cytogenetics and may become more widely used in the cytogenetic laboratories in the upcoming years. Moreover, epigenetic alterations may complement genetic changes for a deeper understanding of the pathogenesis underlying B-cell neoplasms and a more precise risk-based patient stratification. Overall, here we describe the current state of the genomic data integrating chromosomal rearrangements, copy number alterations, and somatic variants, as well as a succinct overview of epigenomic changes, which altogether constitute a comprehensive diagnostic approach in B-cell non-Hodgkin lymphomas.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 4","pages":"Article 101513"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49715976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia 儿童急性淋巴细胞白血病的细胞遗传学和基因组学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-12-01 Epub Date: 2023-08-17 DOI: 10.1016/j.beha.2023.101511

Željko Antić , Jana Lentes , Anke K. Bergmann

{"title":"Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia","authors":"Željko Antić , Jana Lentes , Anke K. Bergmann","doi":"10.1016/j.beha.2023.101511","DOIUrl":"https://doi.org/10.1016/j.beha.2023.101511","url":null,"abstract":"<div>The last five decades have witnessed significant improvement in diagnostics, treatment and management of children with acute lymphoblastic leukaemia (ALL). These advancements have become possible through progress in our understanding of the genetic and biological background of ALL, resulting in the introduction of risk-adapted treatment and novel therapeutic targets, e.g., tyrosine kinase inhibitors for BCR::ABL1-positive ALL. Further advances in the taxonomy of ALL and the discovery of new genetic biomarkers and therapeutic targets, as well as the introduction of targeted and immunotherapies into the frontline treatment protocols, may improve management and outcome of children with ALL. In this review we describe the current developments in the (cyto)genetic diagnostics and management of children with ALL, and provide an overview of the most important advances in the genetic classification of ALL. Furthermore, we discuss perspectives resulting from the development of new techniques, including artificial intelligence (AI).</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 4","pages":"Article 101511"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49716024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac surgery for radiation associated heart disease in Hodgkin lymphoma patients 霍奇金淋巴瘤患者放射相关心脏病的心脏手术治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-10-07 DOI: 10.1016/j.beha.2023.101515

Daniel Shell

引用次数: 0

Donor lymphocyte infusion in Acute Myeloid Leukemia 急性髓性白血病的供体淋巴细胞输注

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 Epub Date: 2023-06-06 DOI: 10.1016/j.beha.2023.101484

Nilay A. Shah

引用次数: 0

Endpoint selection and evaluation in hematology studies 血液学研究的终点选择和评价